Living with Heart Failure?
If you’ve been diagnosed with Chronic Heart Failure for at least 3 months and have been told your heart has a reduced pumping function, you may qualify for a clinical research study aiming to improve outcomes for people living with Heart Failure.
High Blood Pressure Study Pre-Screening
Complete this short form to see if you may qualify for this clinical research study.
Could This Study Be Right for You?
If you’ve been diagnosed with Chronic Heart Failure, you may qualify for this clinical research study.
You May Qualify If:
- You are 18 years of age or older
- You have been diagnosed with Chronic Heart Failure
- You have been living with Heart Failure for at least 3 months
- Your doctor has told you your heart has a reduced pumping function (HFrEF)
- You are currently receiving treatment for Heart Failure
- You are able to attend study visits at our Beltsville, MD location
You May Not Qualify If:
- You are currently taking spironolactone or eplerenone
- You have certain medical conditions that may interfere with study participation
- Your study doctor determines the research study is not appropriate for you
About the Heart Failure Research Study
About the Study
This is a Phase III clinical research study evaluating an investigational treatment for adults living with Chronic Heart Failure with Reduced Ejection Fraction (HFrEF). Researchers are studying whether adding a new investigational medication to standard Heart Failure treatment may help improve outcomes for people living with Heart Failure.
What Is Heart Failure?
Heart Failure doesn’t mean your heart has stopped working—it means your heart isn’t pumping blood as effectively as it should. This can make everyday activities more difficult and may cause symptoms such as shortness of breath, fatigue, and swelling in the legs or feet.
Who We're Looking For
We’re looking for adults 18 years or older who have been diagnosed with Chronic Heart Failure for at least 3 months, have been told their heart has a reduced pumping function (HFrEF), and are currently receiving treatment. If this sounds like you, you may qualify to participate in this research study.
About Dr. Ayim Djamson
Dr. Ayim Djamson is a board-certified cardiologist with more than 20 years of clinical research experience. He has served as Principal Investigator on over 50 Phase II–IV clinical trials, helping advance new treatments for heart-related conditions.
Board-Certified Cardiologist
Dr. Ayim Djamson
MD, FACC
Cardiovascular Research
Leading heart health clinical trials
Patient-Centered Care
Dedicated to safe, compassionate research
About the Heart Failure Research Study
Learn how this study is evaluating a potential new treatment for adults living with Chronic Heart Failure.
Olpasiran (AMG 890) is an investigational medication using RNA interference technology to block Lp(a) production in your liver. Since Lp(a) is genetic and not affected by diet or exercise, this targeted approach may help reduce cardiovascular risk for people with elevated Lp(a). High Lp(a) can’t be controlled with lifestyle changes or standard cholesterol medications, and there are currently no approved Lp(a) treatments on the market. Olpasiran is not yet FDA-approved.
Investigational Treatment
This study is evaluating a potential new medication used alongside standard Heart Failure treatment to better understand its safety and effectiveness.
Advancing Heart Failure Research
Researchers are studying whether this investigational treatment may improve outcomes for adults living with Chronic Heart Failure.
Close Monitoring & Care
Participants receive regular study visits, health assessments, and ongoing monitoring from an experienced cardiovascular research team.
Study Participation
Eligible participants continue their regular Heart Failure care while taking part in scheduled study visits throughout the research study.
Heart Failure Study Pre-Screening
Complete this form to see if you may qualify for the study.
Take the First Step Today
Call (240) 685-2078 or email info@metresearch.org to speak with our research team and learn if you may qualify for this study.Â
Address
10756 Rhode Island
Avenue Beltsville, MD
20705
Hours
Monday – Friday: 9:00 AM – 5:30 PM
Saturday – Sunday: Closed
Transportation
Appointments:
(240) 685-2078
info@metresearch.org
Ready to Get Started? Started?
Complete our short eligibility questionnaire or contact our research team to learn more
about this clinical research study.
Frequently Asked Questions
Who may qualify for this study?
You may qualify if you are 18 years or older, have been diagnosed with Chronic Heart Failure for at least 3 months, have been told your heart has a reduced pumping function (HFrEF), and are currently receiving treatment for Heart Failure.
Will study-related care cost me anything?
No. Qualified participants will receive study-related care at no cost.
Will I receive the investigational treatment?
Participants are randomly assigned to a study group. Depending on the study design, you may receive either the investigational medication or a placebo.
Can I continue seeing my regular doctor?
Yes. Participation in this study does not replace your regular medical care. You should continue seeing your regular healthcare providers throughout the study.
How do I find out if I qualify?
Complete our short eligibility form or contact our research team. We’ll review your information and guide you through the next steps.